Aptamer Group Plc (APTA) AI Stock Analysis

• Market Cap: £20.23M
• Dividend Yield: N/A
• Average Volume (3M): 15.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 39.88%
• EPS Growth: 81.33%
• Country: UK
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 2,696,978,300
• 10 Day Avg. Volume: 14,821,052
• 30 Day Avg. Volume: 15,285,032
• PEG Ratio: 0.04
• Price to Book (P/B): 5.32
• Price to Sales (P/S): 6.11
• P/FCF Ratio: -3.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: 0.76 p ▼(-5.25% Downside)
• Action: Reiterated Date: 12/25/25
• Date: Action: Reiterated 12/25/25

The score is held back primarily by very weak financial performance (sharp revenue decline, ongoing losses, and negative cash flows). Technicals are the main offset, showing a clear uptrend with supportive momentum. Valuation remains constrained by unprofitability and the absence of dividend information.

Positive Factors

Proprietary aptamer platform

Aptamer Group's core focus on proprietary aptamer technology creates a durable competitive moat in a specialized niche. Persistent demand for high-specificity binding agents in diagnostics and drug development supports long-term service revenue and licensing opportunities as clients value validated platform capabilities.

Diversified partnership revenue model

The mix of custom services, direct product sales and partnership agreements provides multiple non-exclusive revenue paths. Upfront and milestone payments reduce reliance on single revenue events and can de-risk R&D investment, aligning cash inflows with project progress over months to years.

Improving leverage position

An improved debt-to-equity ratio reduces financial strain and increases strategic flexibility. Lower leverage helps preserve runway for R&D and commercialization, lowers refinancing risk, and positions the company to withstand cyclical biotech funding cycles over the medium term.

Negative Factors

Severe revenue decline

A near-total revenue drop dramatically weakens the business's scale economics and undermines customer relationships. Persistently low top-line levels limit reinvestment capacity, reduce ability to amortize fixed R&D costs, and threaten long-term viability unless revenue recovery is achieved.

Persistent unprofitability

Ongoing negative EBIT and net margins indicate the core business is not generating returns on capital. Negative ROE and shrinking gross margins erode shareholder value, constrain self-funding of growth initiatives, and likely require external capital to sustain operations and commercial activities.

Negative operating and free cash flow

Persistent operating cash outflows and negative free cash flow create reliance on financing and partnerships to cover burn. This reduces strategic optionality, raises dilution or debt risk, and makes long-term investments or commercialization harder without demonstrable near-term cash recovery.

Aptamer Group Plc Business Overview & Revenue Model

Company Description

Aptamer Group Plc (APTA) is a biotechnology company that specializes in the development of novel aptamer-based technologies for various applications in diagnostics, therapeutics, and research. The company operates primarily in the life sciences sector, focusing on providing high-quality, synthetic aptamers—short, single-stranded oligonucleotides that can bind to specific target molecules. Aptamer Group's core products and services include the design and production of aptamers for use in pharmaceutical development, as well as tools for biomarker discovery and diagnostics.

How the Company Makes Money

Aptamer Group Plc generates revenue through several key streams. Primarily, the company earns income by providing custom aptamer discovery services to pharmaceutical and biotech companies, which are looking for specific binding agents for their drug development processes. Additionally, the company may generate revenue from partnerships and collaborations with industry players that leverage its aptamer technology for research and development purposes. These partnerships often involve upfront payments and milestone payments tied to the progress of joint projects. Furthermore, Aptamer Group may also sell its proprietary aptamer products directly to customers in the diagnostics and life sciences sectors, contributing to its revenue. Overall, the company's financial success is supported by its innovative technology, strategic collaborations, and a growing demand for aptamer-based solutions in the biotechnology industry.

Aptamer Group Plc Financial Statement Overview

Summary

Weak fundamentals: severe revenue decline (-98.8%), persistent losses (negative net/EBIT margins), and negative operating/free cash flow. Balance sheet leverage has improved, but returns remain negative.

Income Statement

Aptamer Group Plc has experienced significant revenue declines, with a negative revenue growth rate of -98.8% in the most recent year. The company is facing substantial losses, as indicated by negative net profit margins and EBIT margins. The gross profit margin has also decreased over time, indicating challenges in maintaining profitability.

Balance Sheet

The company's debt-to-equity ratio has improved, indicating better leverage management. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio is relatively stable, but the overall financial health is weakened by consistent negative returns.

Cash Flow

Aptamer Group Plc's cash flow situation is concerning, with negative operating and free cash flows. Although there is a slight improvement in free cash flow growth, the operating cash flow to net income ratio is negative, indicating cash flow challenges relative to net income.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2022	Jun 2021
Income Statement
Total Revenue	1.20M	860.00K	1.75M	4.04M	1.28M
Gross Profit	350.00K	250.00K	359.00K	2.69M	538.40K
EBITDA	-2.28M	-2.81M	-7.36M	-2.19M	-2.24M
Net Income	-2.42M	-2.96M	-7.84M	-2.09M	-1.85M
Balance Sheet
Total Assets	2.83M	2.77M	2.75M	11.52M	2.06M
Cash, Cash Equivalents and Short-Term Investments	1.06M	870.00K	234.00K	6.69M	369.00K
Total Debt	491.00K	817.00K	1.08M	1.31M	78.00K
Total Liabilities	1.45M	1.88M	2.45M	3.47M	1.96M
Stockholders Equity	1.38M	887.00K	304.00K	8.05M	105.00K
Cash Flow
Free Cash Flow	-2.01M	-2.41M	-6.09M	-2.79M	-1.26M
Operating Cash Flow	-2.00M	-2.28M	-4.06M	-2.38M	-1.10M
Investing Cash Flow	-92.00K	-122.00K	-2.03M	-418.00K	-339.20K
Financing Cash Flow	2.28M	3.04M	-365.00K	9.12M	1.50M

Aptamer Group Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.90, and above the 200-day MA of 0.77, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.87 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.

Aptamer Group Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£74.45M	18.93	66.44%	8.33%	-3.61%	-6.35%
AREC	56 Neutral	£25.86M	-1.64	-197.54%	―	3.31%	21.91%
APTA	52 Neutral	£20.23M	-3.03	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OBD	45 Neutral	£9.65M	-0.59	-316.67%	―	72.17%	79.03%
FAB	44 Neutral	£15.00M	-9.67	-210.32%	―	-11.43%	23.40%
AVCT	42 Neutral	£288.69M	-1.74	-361.23%	―	―	―

Aptamer Group Plc Corporate Events

Aptamer Group launches Optimer radiopharmaceutical push with Radiopharmium

Aptamer Group has launched a targeted radiopharmaceutical development programme in collaboration with Radiopharmium Ltd, aiming to build a proprietary pipeline of Optimer®-based radioconjugates against three high‑value therapeutic targets. The initiative complements an existing partnership with a top‑three global pharma company and is expected to expand the firm’s radiotherapy pipeline to four assets, with in vivo data targeted by the end of 2026.

The company highlights internal data showing Optimer® radioligands exhibiting substantially improved stability versus leading peptide comparators when carrying Lu‑177, which could extend shelf life and simplify manufacturing and logistics if confirmed in further studies. The programme will be led by radiopharmaceutical expert Dr Louis Allott, whose consultancy Radiopharmium will provide radiochemistry and preclinical model access, reinforcing Aptamer’s efforts to differentiate its platform and strengthen its positioning in the fast‑growing targeted radiopharmaceuticals market.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.79 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer Group Updates Status of EMI Share Option Block Listing

Aptamer Group plc has provided an interim review of its block listing related to The Aptamer Group EMI Share Option Scheme, covering the period from 26 August 2025 to 24 February 2026. Over this timeframe, no new options were exercised, 6,000 options lapsed or were waived, leaving 570,053 ordinary shares available for future issuance under the scheme.

The update indicates that Aptamer still retains a substantial pool of unissued shares under the employee share option scheme first admitted in February 2022. This suggests continued flexibility for incentivising staff and management through equity awards without the immediate need for a new admission, which may help align employee interests with long-term shareholder value.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.82 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer Group hits key milestone in Metir pathogen detector collaboration

Aptamer Group plc has completed Phase 1 of its collaboration with Metir plc, achieving the technical feasibility milestone for developing Optimer® binders to detect Cryptosporidium parvum oocysts in water using Metir’s real-time, continuous Pathogen Detector platform. The work, delivered on time and on budget, showed that Cryptosporidium oocysts can be reliably identified with Aptamer’s technology and revealed no material technical barriers.

The collaboration now moves to Phase 2, aiming to finalise and optimise the Cryptosporidium Optimer® binders for commercial use by Q2 2026, enabling Metir to target proof-of-concept field testing in H2 2026 and a commercial launch in early 2027. With Cryptosporidium incidents underscoring the need for rapid, real-time water monitoring and a diagnostic market expected to more than double by 2033, the project highlights the commercial potential of Optimer® technology in continuous detection systems that support regulatory compliance, resilience and public health protection.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.84 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer’s Optimer Tech Powers Twist Bioscience’s New TrueAmp NGS Library Prep Kit

Twist Bioscience has launched its new TrueAmp Library Preparation Kit for next-generation sequencing workflows, incorporating Aptamer Group’s proprietary Optimer binders to enable room-temperature stability and enhanced performance. The kit uses Twist’s in-house ligase and a newly developed TrueAmp polymerase, which is engineered to maximise coverage in difficult genomic regions while maintaining high accuracy.

The TrueAmp kit delivers high yields from low-input or degraded DNA samples, reducing amplification errors and improving data quality, and is validated with Twist’s HT-UDI and UMI adapter systems to support large-scale, multiplexed sequencing. The launch arises from Aptamer’s non-exclusive licensing agreement with Twist Bioscience for an Optimer inhibitor used in a high-fidelity polymerase, underscoring the commercial relevance of Aptamer’s technology and strengthening its position as an enabler in the expanding NGS market.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.84 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer Group Secures New Pharma Contracts and First Cash from Optimer Licensing

Aptamer Group has reported £190,000 of new fee-for-service contracts and extensions, largely driven by repeat Optimer® development work with top‑tier global pharmaceutical companies, lifting its FY26 fee-for-service order book to more than £2.1 million and reinforcing the growing adoption of its platform. The company also received its first £80,000 in cash licensing receipts from a non-exclusive hot‑start PCR Optimer® licence, a high-margin income stream that is expected, based on customer forecasts, to cover around 15% of annual overhead over the next three years, while additional licensing opportunities in diagnostics, tools and therapeutics, combined with a cash runway to June 2027, bolster revenue visibility and management’s confidence in ongoing growth and progress towards cash-flow break-even.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.88 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer Group Reasserts Cash Runway to June 2027 Amid Media Speculation

Aptamer Group plc issued a brief trading update to address media comment and speculation following an earlier announcement, reiterating that its current cash resources provide funding headroom through to June 2027. The confirmation of this cash runway aims to reassure investors and other stakeholders about the company’s near- to medium-term financial stability and its ability to continue executing its strategy without immediate need for additional financing.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer Group lifts H1 revenue 27% as licensing push builds recurring income

Aptamer Group reported a 27% year-on-year rise in unaudited first-half revenue to £0.83 million, backed by a fee-for-service order book of more than £2.0 million for FY26 and a £3.1 million sales pipeline, giving the board confidence that full-year revenue will materially exceed last year. The Group has accelerated its transition from development to commercialisation, signing non-exclusive licensing deals with Twist Bioscience and Alphazyme that bring immediate payments and future royalties, advancing additional licensing discussions for its Optimer® binders in diagnostics and enzymes, and securing a top-three pharmaceutical partner for radioligand development alongside substantial repeat contracts from other top-tier pharma clients. Progress with Unilever programmes, new Optimer® IHC reagents for a global diagnostics company, and a de-risked fibrotic liver therapeutic candidate collectively strengthen Aptamer’s IP base and validate its dual revenue strategy, positioning the company for higher-margin, recurring income streams and reinforcing its standing as a niche technology partner to blue-chip players across pharma, diagnostics and consumer goods.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Aptamer Group Secures Second Enzyme-Modulation Licence with Alphazyme for Hot-Start PCR Optimer

Aptamer Group has signed a non-exclusive worldwide OEM licensing agreement with Alphazyme, a Maravai LifeSciences company, for an enzyme‑modulating Optimer® used in hot‑start PCR and next-generation sequencing applications. The deal, which follows a successful development programme completed in late 2024, includes royalties on Alphazyme’s product sales, milestone payments, and a supply agreement under which Aptamer will manufacture the Optimer®, creating additional revenue streams and supply-chain leverage. The Optimer® binder enables temperature‑sensitive control of key enzyme activities and can replace two traditional antibodies with a single molecule, offering performance and cost advantages; this second enzyme‑modulation licence with Alphazyme is presented by Aptamer as a commercial and technical validation of its Optimer® platform and is expected to support further licensing opportunities and expansion of both companies’ product portfolios.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.77 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.